CompletedPhase 1Results posted

A Phase I Study of LY3502970 in Healthy Participants

A Single-Group, Open-Label, Single-Period, Phase 1 Study to Determine the Absolute Bioavailability of LY3502970 in Healthy Participants

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Healthy volunteers

Eligibility highlights

•BMI 18.5-35•Healthy volunteers

Primary endpoint

•Absolute Bioavailability of LY3502970

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06085482

Org study ID18596

Secondary IDJ2A-MC-GZGOEli Lilly and Company

Timeline

Milestones

Study first posted2023-10-17actual

Study start2023-10-19actual

Primary completion2024-01-05actual

Study completion2024-01-05actual

Last update posted2026-05-27actual

Results first posted2026-05-27actual

Assets

Investigational agents

Orforglipron

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age21 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Are overtly healthy as determined by medical evaluation

•Participants with body weight of 45 kilograms (kg) or more and body mass index within the range 18.5 to 35.0 kilograms per meter squared (kg/m²), inclusive

•Males who agree to use highly effective or effective methods of contraception and women not of childbearing potential may participate in this study

Exclusion criteria

•Participants who have known allergies to LY3502970, related compounds, or any components of the formulation

•Women who are lactating and women of child bearing potential (WOCBP) are excluded from the study

•Participants who regularly use known drugs of abuse or show positive findings on drug screen

Endpoints (14)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

14 endpoints

Primary/registry result

Pharmacokinetics (PK): Absolute Bioavailability of LY3502970

Time frame:Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose; 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose.

descriptive

Posted result

Group	Geometric mean · Percentage	95% CI
LY3502970 + [14C]-LY3502970	77	-

Primary/protocol endpoint

Pharmacokinetics (PK): Absolute bioavailability of LY3502970

Time frame:Predose up to 16 days postdose

descriptive

Secondary/registry result

PK: Area Under the Curve Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞]) of Total Radioactivity in Plasma

Time frame:0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138 hours post-IV dose

concentration, descriptive

Posted result

Group	Geometric mean · nanogram equivalent*hour per milliliter	95% CI
LY3502970 + [14C]-LY3502970	3.71	-

Secondary/registry result

PK: AUC [0-∞] of [14C]-LY3502970 in Plasma

Time frame:0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose

concentration, descriptive

Posted result

Group	Geometric mean · nanogram equivalent*hour per milliliter	95% CI
LY3502970 + [14C]-LY3502970	2.91	-

Secondary/registry result

PK: AUC [0-∞] of LY3502970 in Plasma

Time frame:Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose

concentration, descriptive

Posted result

Group	Geometric mean · nanogram*hour per milliliter	95% CI
LY3502970 + [14C]-LY3502970	108	-

Secondary/registry result

PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma

Time frame:0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138 hours post-IV dose

concentration, descriptive

Posted result

Group	Geometric mean · nanogram equivalent per milliliter	95% CI
LY3502970 + [14C]-LY3502970	2.10	-

Secondary/registry result

PK: Cmax of [14C]-LY3502970 in Plasma

Time frame:0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose

concentration, descriptive

Posted result

Group	Geometric mean · nanogram equivalent per milliliter	95% CI
LY3502970 + [14C]-LY3502970	2.08	-

Secondary/registry result

PK: Cmax of LY3502970 in Plasma

Time frame:Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose

concentration, descriptive

Posted result

Group	Geometric mean · nanogram per milliliter	95% CI
LY3502970 + [14C]-LY3502970	5.43	-

Secondary/protocol endpoint

PK: Area Under the Curve Concentration Versus Time Curve From zero to Infinity (AUC [0-∞]) of Total Radioactivity

Time frame:Predose up to 16 days postdose

AUC₀-∞

concentration, descriptive

Secondary/protocol endpoint

PK: AUC [0-∞] of [14C]-LY3502970

Time frame:Predose up to 16 days postdose

AUC₀-∞

concentration, descriptive

Secondary/protocol endpoint

PK: AUC [0-∞] of LY3502970

Time frame:Predose up to 16 days postdose

AUC₀-∞

concentration, descriptive

Secondary/protocol endpoint

PK: Maximum Concentration (Cmax) of Total Radioactivity

Time frame:Predose up to 16 days postdose

Cmax

concentration, descriptive

Secondary/protocol endpoint

PK: Cmax of [14C]-LY3502970

Time frame:Predose up to 16 days postdose

Cmax

concentration, descriptive

Secondary/protocol endpoint

PK: Cmax of LY3502970

Time frame:Predose up to 16 days postdose

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.